Roivant will host a conference call on February 10, 2025, to discuss Q3 financial results and business updates.
Quiver AI Summary
Roivant announced a live conference call and webcast scheduled for February 10, 2025, at 8:00 a.m. ET to discuss its financial results for the third quarter ending December 31, 2024, along with a business update. Interested participants can register online to join the call, with access details available on Roivant's website. The press release highlights Roivant as a biopharmaceutical company focused on accelerating the development of important medicines, featuring products like IMVT-1402, batoclimab, brepocitinib, and mosliciguat in its pipeline. Additionally, the release includes forward-looking statements regarding the company's expectations and potential regarding its products and market position.
Potential Positives
- Roivant plans to provide financial results and a business update during a live conference call on February 10, 2025, which will inform investors and stakeholders of the company's progress.
- The company highlights its robust pipeline of product candidates, including several therapies targeting significant diseases, which reflects its commitment to advancing innovative treatments.
- The archived webcast of the conference call will ensure that interested parties have access to the information shared, promoting transparency and investor engagement.
Potential Negatives
- The press release heavily relies on forward-looking statements, which may heighten investor skepticism regarding the company's future performance given the inherent risks and uncertainties outlined.
- The mention of operating in a "very competitive and rapidly changing environment" suggests that Roivant may face significant challenges in advancing its products and potentially indicates vulnerability to competitors.
- The lack of specific financial results or updates in the press release could lead to uncertainty among investors about the company's current performance and trajectory, particularly as it prepares to report financials on February 10, 2025.
FAQ
When is Roivant's third quarter financial results conference call?
Roivant will host the call on February 10, 2025, at 8:00 a.m. ET.
Where can I access the conference call registration?
You can register for the conference call online using the provided registration link.
Will there be a replay of the conference call?
Yes, an archived webcast will be available on Roivant’s website after the call.
What products are in Roivant's pipeline?
The pipeline includes IMVT-1402, batoclimab, brepocitinib, and mosliciguat among others.
How does Roivant support its drug development?
Roivant creates nimble subsidiaries called “Vants” to develop and commercialize its medicines and technologies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ROIV Insider Trading Activity
$ROIV insiders have traded $ROIV stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales.
Here’s a breakdown of recent trading of $ROIV stock by insiders over the last 6 months:
- DANIEL ALLEN GOLD has made 0 purchases and 6 sales selling 4,426,000 shares for an estimated $51,820,727.
- MATTHEW GLINE (CEO) sold 1,983,257 shares for an estimated $23,382,600
- MAYUKH SUKHATME (Pres&Chief Investment Officer) has made 0 purchases and 4 sales selling 1,298,821 shares for an estimated $15,613,376.
- FINANCIAL LP QVT has made 0 purchases and 2 sales selling 926,000 shares for an estimated $10,942,820.
- ERIC VENKER (President & COO) has made 0 purchases and 6 sales selling 754,604 shares for an estimated $8,715,662.
- KEITH S MANCHESTER has made 0 purchases and 2 sales selling 503,000 shares for an estimated $5,866,308.
- RAKHI KUMAR (Chief Accounting Officer) sold 250,000 shares for an estimated $2,972,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ROIV Hedge Fund Activity
We have seen 169 institutional investors add shares of $ROIV stock to their portfolio, and 131 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 33,491,231 shares (+408.8%) to their portfolio in Q3 2024, for an estimated $386,488,805
- VIKING GLOBAL INVESTORS LP removed 15,056,780 shares (-21.8%) from their portfolio in Q3 2024, for an estimated $173,755,241
- BLACKROCK, INC. added 6,591,789 shares (+18.6%) to their portfolio in Q3 2024, for an estimated $76,069,245
- SB INVESTMENT ADVISERS (UK) LTD removed 5,427,314 shares (-7.6%) from their portfolio in Q3 2024, for an estimated $62,631,203
- TOMS CAPITAL INVESTMENT MANAGEMENT LP added 4,015,000 shares (+inf%) to their portfolio in Q3 2024, for an estimated $46,333,100
- CITADEL ADVISORS LLC added 4,004,146 shares (+208.1%) to their portfolio in Q3 2024, for an estimated $46,207,844
- BVF INC/IL removed 2,742,409 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $31,647,399
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BASEL, Switzerland and LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, February 10, 2025, to report its financial results for the third quarter ended December 31, 2024, and provide a business update.
To access the conference call by phone, please register online using this registration link . The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.
About Roivant
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information,
www.roivant.com
.
Roivant Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.
Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates following applicable regulatory approvals. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.
Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Investors
Keyur Parekh
[email protected]
Media
Stephanie Lee
[email protected]